NEW YORK (GenomeWeb News) – Epigenomics today reported a 6 percent increase year over year in third-quarter revenues.

The Berlin, Germany-based firm said that for the three months ended Sept. 30 revenues totaled €272,000 ($347,000), up from €257,000 a year ago as an increase in R&D service fees offset a decrease in licensing revenues.

Epigenomics' net loss narrowed to €3.7 million, or €.42 per share, compared to a net loss of €4.8 million, or €.55 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Nov
09
Sponsored by
NuGEN

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.